PLoS Pathogens (Oct 2014)

Mycobacterial antigen driven activation of CD14++CD16- monocytes is a predictor of tuberculosis-associated immune reconstitution inflammatory syndrome.

  • Bruno B Andrade,
  • Amrit Singh,
  • Gopalan Narendran,
  • Melissa E Schechter,
  • Kaustuv Nayak,
  • Sudha Subramanian,
  • Selvaraj Anbalagan,
  • Stig M R Jensen,
  • Brian O Porter,
  • Lis R Antonelli,
  • Katalin A Wilkinson,
  • Robert J Wilkinson,
  • Graeme Meintjes,
  • Helen van der Plas,
  • Dean Follmann,
  • Daniel L Barber,
  • Soumya Swaminathan,
  • Alan Sher,
  • Irini Sereti

DOI
https://doi.org/10.1371/journal.ppat.1004433
Journal volume & issue
Vol. 10, no. 10
p. e1004433

Abstract

Read online

Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is an aberrant inflammatory response occurring in a subset of TB-HIV co-infected patients initiating anti-retroviral therapy (ART). Here, we examined monocyte activation by prospectively quantitating pro-inflammatory plasma markers and monocyte subsets in TB-HIV co-infected patients from a South Indian cohort at baseline and following ART initiation at the time of IRIS, or at equivalent time points in non-IRIS controls. Pro-inflammatory biomarkers of innate and myeloid cell activation were increased in plasma of IRIS patients pre-ART and at the time of IRIS; this association was confirmed in a second cohort in South Africa. Increased expression of these markers correlated with elevated antigen load as measured by higher sputum culture grade and shorter duration of anti-TB therapy. Phenotypic analysis revealed the frequency of CD14(++)CD16(-) monocytes was an independent predictor of TB-IRIS, and was closely associated with plasma levels of CRP, TNF, IL-6 and tissue factor during IRIS. In addition, production of inflammatory cytokines by monocytes was higher in IRIS patients compared to controls pre-ART. These data point to a major role of mycobacterial antigen load and myeloid cell hyperactivation in the pathogenesis of TB-IRIS, and implicate monocytes and monocyte-derived cytokines as potential targets for TB-IRIS prevention or treatment.